(NASDAQ: MCRB) Seres Therapeutics's forecast annual revenue growth rate of 5.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Seres Therapeutics's revenue in 2024 is $126,847,000.On average, 1 Wall Street analysts forecast MCRB's revenue for 2024 to be $45,434,329, with the lowest MCRB revenue forecast at $45,434,329, and the highest MCRB revenue forecast at $45,434,329. On average, 1 Wall Street analysts forecast MCRB's revenue for 2026 to be $15,744,509,441, with the lowest MCRB revenue forecast at $15,744,509,441, and the highest MCRB revenue forecast at $15,744,509,441.
In 2027, MCRB is forecast to generate $1,449,355,092 in revenue, with the lowest revenue forecast at $1,449,355,092 and the highest revenue forecast at $1,449,355,092.